Sign in
Taking peopleNo phase

Light therapy and memory training for amnestic mild cognitive impairment

Tests light therapy plus memory training in amnestic mild cognitive impairment.

Key facts

Who runs it
Uskudar University
Where
Türkiye2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Effects of Photobiomodularion on Brain Connectivity and Cognitive Function in Cognitive Impairment
Status
Recruiting
People taking part
60 people, planned
Started
30 Mar 2024
Planned end
Oct 2026
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Active transcranial Photobiomodulation
  • sham transcranial Photobiomodulation
  • Cognitive Rehabilitation
Record updated
17 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 55 or older with amnestic mild cognitive impairment (aMCI), a memory problem greater than normal aging. It tests a light-based brain treatment together with memory training.

Age
55 years or older
Sex
All sexes can join
Disease stage
A diagnosis of amnestic mild cognitive impairment (aMCI)

Main reasons for not taking part

  • Having a neurological disorder (a disease of the brain or nerves)
  • Having a severe mental health disorder
  • Having a pacemaker or other implanted medical device that is not safe in an MRI scanner

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Age 55 years or older
  • Diagnosis of amnestic Mild Cognitive Impairment (aMCI)

Who cannot take part

  • Presence of a neurological disorder
  • Presence of a severe psychiatric disorder
  • Having a pacemaker or other implanted medical device that is not MRI-compatible

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if transcranial photobiomodulation (t-PBM), a light-based brain therapy, can help improve memory and cognitive skills in older adults with amnestic mild cognitive impairment (aMCI). This condition involves memory problems that are greater than normal aging and may increase the chance of developing Alzheimer's disease.

Read full original descriptionShow less

The main questions this study aims to answer are:

1. Does t-PBM, when used together with cognitive training, improve memory and cognitive skills? 2. Does t-PBM change how certain brain areas communicate with each other, especially in the default mode network (DMN)?

Researchers will compare:

t-PBM plus cognitive training to sham (inactive) t-PBM plus the same cognitive training to see if the active light treatment leads to better cognitive improvement and healthier brain activity.

Participants will:

* Provide a blood sample so the research team can create a genetic profile; * Complete cognitive tests before and after the 4-week program; * Meet with a dietitian before and after the program so the research team can make sure diet stays consistent and does not influence brain results; * Have a brain fMRI scan before and after treatment to measure brain connectivity changes; * Take part in eight sessions of cognitive training; * Receive either active t-PBM or sham t-PBM during these sessions.

The 2 groups in the trial

  • Intervention Arm: Active TreatmentTreatment being tested

    Participants in this arm will receive active transcranial photobiomodulation delivered at gamma frequency while simultaneously participating in a structured cognitive rehabilitation session. The photobiomodulation device will be placed on the participant's head and will operate continuously for 20 minutes during each session. Cognitive rehabilitation tasks will be administered throughout the stimulation period to enhance cognitive engagement. This combined intervention will be applied across all scheduled treatment sessions.

    Treatment: Active transcranial Photobiomodulation and Cognitive Rehabilitation

  • Control Arm: Sham/PlaceboSham treatment, for comparison

    Participants in this arm will receive sham transcranial photobiomodulation while completing the same cognitive rehabilitation session provided to the experimental group. The device will be placed on the participant's head and will appear to operate normally; however, no active light output will be delivered. Each session lasts 20 minutes, during which participants complete standardized cognitive rehabilitation tasks. Session frequency, duration, and rehabilitation procedures are identical to the experimental arm to maintain blinding and ensure comparable conditions.

    Treatment: sham transcranial Photobiomodulation and Cognitive Rehabilitation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effects of Transcranial Photobiomodulation (t-PBM) on Cognitive Performance and Functional Brain Connectivity in Patients With Mild Cognitive Impairment and the Role of Genetic Factors
Plain-language title
Light therapy and memory training for amnestic mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
17 December 2025